FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Shuichi Hironaka

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Disorders

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Takahiro Tsushima; Kentaro Yamazaki; Hirofumi Yasui; Hiroya Taniguchi; Akiko Todaka; Narikazu Boku; Akira Fukutomi; Shuichi Hironaka; Nozomu Machida; Yusuke Onozawa; Keisei Taku
Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.
T Doi; Akira Fukutomi; Shuichi Hironaka; Wasaburo Koizumi; Atsushi Ohtsu; Y Onozawa; Narikazu Boku; T Yoshino; T Sasaki
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
Hiroto Ishiki; Takashi Kojima; Nozomu Machida; Narikazu Boku; Akira Fukutomi; Takayuki Hashimoto; Shuichi Hironaka; Yusuke Onozawa; Keisei Taku; Kentaro Yamazaki; Hirofumi Yasui; Tetsuo Nishimura
Nutrition support for head and neck squamous cell carcinoma patients treated with chemoradiotherapy: how often and how long?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Shuichi Hironaka (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Takahiro Tsushima; Kentaro Yamazaki; Hirofumi Yasui; Hiroya Taniguchi; Akiko Todaka; Narikazu Boku; Akira Fukutomi; Shuichi Hironaka; Nozomu Machida; Yusuke Onozawa; Keisei Taku
Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.
International journal of clinical oncology 2013;18(1):10-6.
2012: T Doi; Akira Fukutomi; Shuichi Hironaka; Wasaburo Koizumi; Atsushi Ohtsu; Y Onozawa; Narikazu Boku; T Yoshino; T Sasaki
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
British journal of cancer 2012;107(3):429-34.
2012: Hiroto Ishiki; Takashi Kojima; Nozomu Machida; Narikazu Boku; Akira Fukutomi; Takayuki Hashimoto; Shuichi Hironaka; Yusuke Onozawa; Keisei Taku; Kentaro Yamazaki; Hirofumi Yasui; Tetsuo Nishimura
Nutrition support for head and neck squamous cell carcinoma patients treated with chemoradiotherapy: how often and how long?
ISRN oncology 2012;2012():274739.
2010: Takahiro Tsushima; Shuichi Hironaka; Narikazu Boku; Nozomu Machida; Kentaro Yamazaki; Hirofumi Yasui; Keisei Taku; Akira Fukutomi; Yusuke Onozawa
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2010;13(4):245-50.
2010: Takeshi Sakamoto; Hirofumi Yasui; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Kentaro Yamazaki; Keisei Taku; Nozomu Machida; Akiko Todaka; Hideharu Tomita; Takahiro Tsushima; Hiroya Taniguchi; Satoshi Hamauchi
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
International journal of clinical oncology 2010;15(3):287-93.
2009: Akira Ono; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Hiroshi Yasui; Kentaro Yamazaki; Takayuki Yoshino; Keisei Taku; Takashi Kojima
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Japanese journal of clinical oncology 2009;39(5):332-5.
2009: Rai Shimoyama; Hirofumi Yasui; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Kentaro Yamazaki; Keisei Taku; Takashi Kojima; Nozomu Machida; Akiko Todaka; Hideharu Tomita; Takeshi Sakamoto; Takahiro Tsushima
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2009;12(4):206-11.
2009: Masako Imazawa; Takashi Kojima; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Hirofumi Yasui; Kentaro Yamazaki; Keisei Taku
Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2009;12(3):153-7.
2008: Koji Nakashima; Shuichi Hironaka; Narikazu Boku; Yusuke Onozawa; Akira Fukutomi; Kentaro Yamazaki; Hirofumi Yasui; Keisei Taku; Takashi Kojima; Nozomu Machida
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Japanese journal of clinical oncology 2008;38(12):810-5.
2008: Nozomu Machida; Takayuki Yoshino; Narikazu Boku; Shuichi Hironaka; Yusuke Onozawa; Akira Fukutomi; Kentaro Yamazaki; Hirofumi Yasui; Keisei Taku; Masahiro Asaka
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Japanese journal of clinical oncology 2008;38(10):689-94.
2008: Kentaro Yamazaki; Shuichi Hironaka; Narikazu Boku; Hirofumi Yasui; Akira Fukutomi; Takayuki Yoshino; Yusuke Onozawa; Noriaki Hasuike; Tetsuya Inui; Yuichiro Yamaguchi; Hiroyuki Ono
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
International journal of clinical oncology 2008;13(2):150-5.
2008: Sadamoto Zenda; Shuichi Hironaka; Narikazu Boku; Kentaro Yamazaki; H Yasui; Akira Fukutomi; Takayuki Yoshino; Yusuke Onozawa; Tetsuo Nishimura
Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E 2008;21(3):195-200.
2007: Takayuki Yoshino; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Yuichiro Yamaguchi; Noriaki Hasuike; Kentaro Yamazaki; Nozomu Machida; Hiroyuki Ono
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Japanese journal of clinical oncology 2007;37(9):686-91.
2007: Kentaro Yamazaki; Narikazu Boku; Kaoru Shibamoto; Hirofumi Yasui; Akira Fukutomi; Takayuki Yoshino; Shuichi Hironaka; Yusuke Onozawa; Yosuke Otake; Noriaki Hasuike; Hiroyuki Matsubayashi; Tetsuya Inui; Yuichiro Yamaguchi; Hiroyuki Ono
The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer.
Japanese journal of clinical oncology 2007;37(2):96-101.
2006: Shinya Ueda; Shuichi Hironaka; Narikazu Boku; Akira Fukutomi; Takayuki Yoshino; Yusuke Onozawa
Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2006;9(3):203-7.
2006: Shuichi Hironaka; Sadamoto Zenda; Narikazu Boku; Akira Fukutomi; Takayuki Yoshino; Yusuke Onozawa
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2006;9(1):14-8.
2005: Masaki Matsuoka; Narikazu Boku; Takayuki Yoshino; Shuichi Hironaka; Yusuke Onozawa; Akira Fukutomi; Sadamoto Zenda; Kentaro Yamazaki; Hirofumi Yasui; Noriaki Hasuike; Tetsuya Inui; Yuichiro Yamaguchi; Hiroyuki Ono; Minoru Kamata
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel.
International journal of clinical oncology 2005;10(6):429-32.
2005: Makoto Tahara; Atsushi Ohtsu; Shuichi Hironaka; Narikazu Boku; Satoshi Ishikura; Yoshinori Miyata; Takashi Ogino; Shigeaki Yoshida
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
Japanese journal of clinical oncology 2005;35(6):316-23.
2003: Shuichi Hironaka; Atsushi Ohtsu; Narikazu Boku; Manabu Muto; Fumio Nagashima; Hiroki Saito; Shigeaki Yoshida; Mitsuyo Nishimura; Masatora Haruno; Satoshi Ishikura; Takashi Ogino; Seiichiro Yamamoto; Atsushi Ochiai
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.
International journal of radiation oncology, biology, physics 2003;57(2):425-33.
2003: Satoshi Ishikura; Keiji Nihei; Atsushi Ohtsu; Narikazu Boku; Shuichi Hironaka; Kiyomi Mera; Manabu Muto; Takashi Ogino; Shigeaki Yoshida
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2697-702.
2002: Manabu Muto; Shuichi Hironaka; Mari Nakane; Narikazu Boku; Atsushi Ohtsu; Shigeaki Yoshida
Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer.
Gastrointestinal endoscopy 2002;56(4):517-21.
2002: Shuichi Hironaka; Takahiro Hasebe; Tomoyuki Kamijo; Atsushi Ohtsu; Narikazu Boku; Shigeaki Yoshida; Hiroki Saitoh; Atsushi Ochiai
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):124-30.
2001: Makoto Tahara; Atsushi Ohtsu; Narikazu Boku; Fumio Nagashima; Manabu Muto; yasushi sano; M Yoshida; Kiyomi Mera; Shuichi Hironaka; H Tajiri; Shigeaki Yoshida
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2001;4(4):212-8.